Dry AMD accounts for about 85–90 per cent of all AMD cases. Wet (neovascular or exudative) macular degeneration accounts for only 10–15 per cent of AMD, but causes most cases of severe vision loss. Complement and coagulation cascades, chaperones, and glycolysis pathways were significant in wet AMD, whereas matrix remodelling pathways were enriched mostly in dry AMD. This next study examines the long-term effectiveness of anti-VEGF therapy in managing neovascular age-related macular degeneration (nAMD). Meta-regression showed that mean VA change was greater in those with a lower baseline VA and those treated with a higher number of injections over 10 years.